BioSpace News Archive

Dupixent™ can significantly reduce the constant itch and improve the skin’s overall condition

Citius Pharmaceuticals, Inc. announced the closing of the previously announced underwritten at-the-market offering of 7,821,230 shares of its common stock and common warrants to purchase up to an aggregate of 7,821,230 shares of Common Stock.

Robert R. Redfield, MD, the Director of the Centers for Disease Control and Prevention (CDC), will make remarks at an October 16 National Press Club Headliners Luncheon about the importance of immunization as the winter flu season is set to begin.

22NW, LP is one of the largest shareholders of Catalyst Biosciences, Inc with ownership of approximately 6% of the Company’s outstanding shares.

Use of hēRo3℠ Platform by Drug Pricing Watchdog Following Conclusion of Pilot Transparency Initiative Confirms ICER’s Commitment to Cloud-Based Tools

Winners of the Pfizer Golden Ticket Program announced last night during a panel discussion and networking event at Pfizer’s Cambridge, MA R&D site

SpendEdge, a leading provider of supply market intelligence solutions, has announced the completion of their latest success story on reducing the expenditure by 23% for a medical device manufacturer by performing supply market assessment.

Mylan N.V. announced that it has finalized a previously disclosed civil settlement with the U.S. Securities and Exchange Commission.

Genentech, a member of the Roche Group, announced positive data from the Phase III IMpower110 study evaluating Tecentriq® as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations.

The patient lifting devices market is expected to post a CAGR close to 8% during the period 2019-2023, according to the latest market research report by Technavio.